Alvotech
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassi...
Latest News
4 days ago · marketbeat.com
What Alvotech (ALVO) Said on Its Q3 Earnings CallAlvotech NASDAQ: ALVO expects its full-year revenue and adjusted earnings to land near the lower end of its guidance range, as the biosimilar maker works to increase deliveries following a manufacturing slowdown.
5 days ago · zacks.com
Alvotech (ALVO) Reports Q3 Loss, Lags Revenue EstimatesAlvotech (ALVO) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.02 per share a year ago.
5 days ago · globenewswire.com
Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business UpdateREYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the nine months to September 30, 2026, and provided a business update.
13 days ago · zacks.com
Will Alvotech (ALVO) Report Negative Earnings Next Week? What You Should KnowAlvotech (ALVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
14 days ago · seekingalpha.com
Alvotech: The Market Is Still Pricing The Broken FactoryAlvotech is transitioning from supply remediation to throughput, with FDA-cleared facilities and multiple key biosimilar filings advancing toward decisions this quarter. ALVO's guidance implies a significant second-half revenue and EBITDA ramp, hinging on restored manufacturing capacity and upcoming product launches. Recent manufacturing upgrades and expanded partnerships position ALVO to compete on supply reliability and cost, crucial in crowded biosimilar markets.
15 days ago · globenewswire.com
Alvotech to Present at Upcoming Investor Conferences in NovemberREYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that members of the management team will participate in upcoming investor conferences in November as follows:
20 days ago · globenewswire.com
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026REYKJAVIK, ICELAND (October 28, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its financial results for the nine months and third quarter ended September 30, 2026 on Wednesday, November 11, 2026, after the U.S. market close.
27 days ago · zacks.com
New Strong Sell Stocks for October 21stALVO, CSIQ and AESI have been added to the Zacks Rank #5 (Strong Sell) List on October 21, 2026.
28 days ago · globenewswire.com
Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batchEnhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech's biosimilars portfolio
1 month ago · globenewswire.com
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mgAVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg)
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ALVO